Garazzino Silvia, Altieri Elena, Silvestro Erika, Pruccoli Giulia, Scolfaro Carlo, Bignamini Elisabetta
Department of Child Pathology and Treatment "Regina Margherita", Unit of Infectious Diseases, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy.
Postgraduate School of Pediatrics, University of Turin, Turin, Italy.
Front Pediatr. 2020 May 5;8:173. doi: 10.3389/fped.2020.00173. eCollection 2020.
Ceftolozane-tazobactam is a novel fifth-generation cephalosporin/β-lactamase inhibitor combination recently approved for treatment of both complicated intra-abdominal and urinary tract infections in adults. Considering its potent bactericidal activity against , it might represent an important option also for treating children with exacerbations of cystic fibrosis due to when other alternative treatments have been exhausted. We hereby review available data on the use of ceftolozane-tazobactam in children, focusing on cystic fibrosis.
头孢洛扎-他唑巴坦是一种新型的第五代头孢菌素/β-内酰胺酶抑制剂组合，最近被批准用于治疗成人复杂性腹腔内感染和尿路感染。鉴于其对……具有强大的杀菌活性，当其他替代治疗方法都已用尽时，它可能也是治疗因……而病情加重的囊性纤维化儿童的一个重要选择。我们在此回顾关于头孢洛扎-他唑巴坦在儿童中使用的现有数据，重点关注囊性纤维化。
